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ABSTRACT 
Neuroaxonal dystrophies are a group of clinically and genetically hetrerogeneous 
neurodegenerative disorders. In classic infantile neuroaxonal dystrophy (INAD) patients 
present with psychomotor regression, neurological deterioration and progressive optic 
atrophy. Mutations in the PLA2G6 gene are responsible for this phenotype. Case series report 
of this very rare condition. We describe the clinical findings of 3 unrelated portuguese INAD 
patients. Standard complete clinical and ophthalmological characterization were undertaken, 
ompleted with automated sequencing of the PLA2G6 gene.. We present the molecular 
findings and try to establish potential genotype-phenotype correlation.  
 
RESUMO 
As distrofias neuroaxonais englobam um grupo de patologias neurodegenerativas 
clinicamente e geneticamente heterogéneas. Doentes com distrofia neuroaxonal infantil 
clássica (INAD) apresentam uma clínica de regressão psicomotora, deterioração neurológica 
e atrofia ótica progressiva. Mutações no gene PLA2G6 são responsáveis por este fenótipo. 
Apresentamos neste trabalho achados clínicos em 3 doentes portugueses com INAD, sem 
relação de parentesco. Foi realizada uma caracterização oftalmológica completa e análise 
molecular por sequenciação automática do gene PLA2G6. Descrevemos os achados clínicos 
e moleculares destes doentes e analisamos potenciais relações genótipo-fenótipo 
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ABBREVIATIONS: 
Atypical NAD: Atypical Neuroaxonal Dystrophy 
NBIA: neurodegeneration with iron accumulation 
CNS: central nervous system 
EEG: electroencephalogram 
EMG: electromyogram 
INAD: Infantile Neuroaxonal Dystrophy 
iPLA2-VIA: group 6 phospholipase A2 
MRI: magnetic resonance imaging 
OMIM: Online Mendelian Inheritance in Man 
PKAN: Phantothenate Kinase-Associated Neurodegeneration  
PLA2G6: group 6 phospholipase A2 gene 
PLAN: PLA2G6-Associated Neurodegeneration 
 
INTRODUCTION 
 
Neurodegeneration with Brain Iron Accumulation disorders (NBIA) overlie a 
homogenous group of inherited diseases that compound a common physiopathologic basis, 
despite the different genetic etiology and clinical outcomes. By definition, these disorders are 
characterized by the abnormal accumulation of iron in the basal ganglia  The exact 
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relationship between iron accumulation and the symptoms of NBIA is not fully understood 
For most of these conditions, we cannot find a significantly large body of knowledge 
according to each complete metabolic and transcriptional pathway that lead to the gradual 
degeneration process. (Essay, 2013) For this reason, at this time, there is no cure. 
Currently, there are nine identified forms of NBIA, although the majority of cases may 
be included in two sub-types: Phantothenate Kinase-Associated Neurodegeneration (PKAN) 
or Hallervorden–Spatz syndrome secondary to mutations in the PANK2 gene, which is the 
most common of all NBIAs, appearing in a context of extra-pyramidal symptoms; and 
PLA2G6-Associated Neurodegeneration (PLAN), which may present two different clinical 
phenotypes, namely Infantile Neuroaxonal Dystrophy (INAD, #no. 256600 in OMIM), as the 
early-onset form, and Atypical Neuroaxonal Dystrophy, the late onset form. (Khateeb et al., 
2006). The incidence of NBIAs is estimated to have a frequency of 3 per 1 million individuals 
and equally affects males and females. Because rare conditions like NBIA often go 
unrecognized, these disorders may be underdiagnosed or misdiagnosed, making it difficult to 
determine the accuracy of these estimates. (Kurian et al  2011) 
INAD, also known as Seitelberger’s disease, is an autosomal dominant condition 
which results from mutations in the PLA2G6 gene; to date 44 distinct mutations have been 
described. The PLA2G6 gene maps on the long arm of chromosome 22 (22q13.1), and 
encodes cytosolic Ca
2+
 -independent phospholipase A2, group VIA (iPLA2-VIA), which is a 
critical enzyme crucial for maintenance of cell membrane homeostasis. As previously stated, 
researchers are yet to find a direct relationship between this malfunctioning enzyme and iron 
deposition in axons, leading to the formation of spheroids. (Strokin et al, 2012) 
iPLA2-VIA participates in a complex pathway of homeostasis upholding. As a Ca
2+
-
independent enzyme, it regulates the finalization of a yet incompletely understood 
mechanism. It is known that VIA iPLA2 has been shown to be essential to activate Orai1, a 
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pore-forming subunit that undertakes the Ca
2+
 release-activated Ca
2+ 
channels. Though it has 
been demonstrated that Orai1 needs to be modified in order to launch a Ca
2+
 compensation. 
This signaling is established indirectly by the stromal interaction molecule 1, when a lack of 
Ca
2+
 is sensed in the Endoplasmic Reticulum storage. The reason why these storages run out 
of Ca
2+
 is explained by a mechanism of hydrolysis of Phosphatidyl-4,5-biphosphate, a 
specific phospholipid component of the cell membrane. This hydrolysis is performed by 
Phospholipase C, forming InsP3 (Inositol 1,4,5-Trisphosphate), which engages a second-
messaging process to Gq protein-coupled metabolotropic receptor on the ER storages, 
inducing the aforementioned Ca
2+
storage deflation (Strokin et al., 2012) 
Mutations in the PLA2G6 gene may trigger a lack of this Ca
2+
 compensatory 
mechanism which, in turn, may lead to a breach in cellular homeostasis, fatty acid 
accumulation, lysophospholipid accumulation, and then, a modification of the membrane 
composition and, ultimately, a change in cellular structure. This feature will somehow trigger 
a process that results in the deposition of iron, causing the appearance of symptoms that will 
lead to either phenotype: INAD or Atypical NAD. (Strokin et al., 2012) 
We present a group of 3 unrelated INAD patients who present some distinct features 
from those expected in typical INAD.  
INAD usually includes early-onset of disrupted development symptoms, starting 
before the age of 3; later presentations are quite rare. Affected children usually display 
progressive psychomotor delay or regression, associated with symmetric pyramidal signs 
(Babinsky sign is usually present). These signs comprise hypotonia, spastic tetraplegia and 
lower limb hyporreflexia. Convulsive frames may be also associated with INAD patients, 
which can be in part explained emphasizing the fact we are discussing neurologic features of 
young children, to whom these expressions are frequently associated. For these reason, this 
peculiarity is not fully considered as INAD parameter, along with lower limb hyporreflexia. 
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Ophthalmological signs and symptoms comprise insidious optic atrophy (noticed between 10 
and 24 months of age) underlying the decrease of visual acuity and appearance of manifest 
sensory nystagmus (which may represent the first manifestation). Disease evolves rapidly 
with continuous motor and cognitive deterioration and most patients die before age 10. 
(Kurian et al, 2011)  
Atypical NAD, as a juvenile presentation form, is a rare condition among the NBIA 
disorders. However, as a PLA2G6-associated disease, has a typical set of manifestations, 
including seizures, myoclonus, progressive ataxia and dementia. Prenatal or neonatal forms 
have also been described. (Zhang et al., 2013)  
INAD should be considered in a child with psychomotor regression or arrest, 
associated with a progression of locomotive deficit, and, mainly, an insidious increase of 
hypotonia and muscular weakness from 6 to 12 months old. (Carrilho et al., 2008) 
Among the supplementary diagnostic exams, EEG.should be underscored. It should be 
performed after the identification of the first disease manifestations, and periodically to 
follow-up the degenerative process. INAD patients usually show records of fast rhythms with 
high amplitude, both in vigil and non-vigil states. Nevertheless, these characteristics are not 
pathognomonic of INAD, and diagnosis should always be clinically supported. Furthermore, 
these fast rhythms are hardly ever observed before age 2; recent studies, however, have 
documented some exceptions. Hence, we should investigate these fast rhythms, particularly 
those of early-onset, which can be confused for muscle artifacts, sleep spindles or drug-
induced beta activity. Background activity is frequently normal, though occasionally slow. 
Also slow waves and epileptiform activity can be found on EEG. (Carrilho et al., 2008) 
Even in patients who have confirmed INAD by molecular testing, EMG may fail to 
evidence degeneration. (Carrilho et al., 2008) 
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INAD patients present some distinctive MRI findings, such as insidious atrophy of the 
inferior cerebellar vermix, presence of T2-weighted hypersignal of the cerebellar cortex (these 
changes may be identified at disease presentation) and hypointensity of the globus pallidus 
and substantia nigra (detected in later stages and explained by iron deposition). Differential 
diagnosis may be MRI-assisted: patients with PKAN evidence the “tiger eye signal”, which 
helps the exclusion of any NBIA by PLAN. (Rossi et al., 2012) 
MRI spectroscopy also provides some important clues to diagnosis; some studies have 
identified N-acetylaspartate reduction and the presence of lactate in the basal ganglia. (Mader 
I et al, 2001). In order to avoid peripheral biopsy, a neuropediatrician/geneticist suspect a 
INAD diagnosis upon observing, comparing and interrelating neurophysiological studies and 
cerebral MRI, with subsequent molecular confirmation derived from mutation screening of 
the PLA2G6 gene. (Carrilho et al., 2008) 
Prior to molecular testing and in the rare cases where molecular testing fails to identify 
the genetic cause, INAD may be highly suspected from skin and peripheral nerve biopsy 
findings. As a pathologic signature, these biopsies may identify axonal edema, and the 
presence of neuroaxonal spheroids, present along the CNS and unmyelinated peripheral nerve 
endings of skin and conjunctiva. Electron microscopy (EM) examination may assist in clearly 
distinguishing these structures. Although the recognition of these spheroids is difficult, their 
evidence in a biopsy can be extremely important, especially in those patients in which no 
PLA2G6 mutations are found, despite strong clinical suspicion. (Carrilho et al., 2008) 
Prenatal diagnosis is essential in this devastating entity. However, some in utero 
studies have been reflecting peculiar and characteristic signs of a Fetal Neuroaxonal 
Dystrophy, not regarding, this way, a mutation that is PLA2G6 related. This different genetic 
profile may show an even earlier onset and, therefore, a different pathophysiological and 
clinical approach.  
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Schindler disease is a differential diagnosis, which is caused by mutations in the -N-
acetilgalactosaminidasis (NAGA) gene and may be difficult to differentiate from INAD, both 
in clinical and histological terms. This lysosomal storage disease presents with severe 
psychomotor retardation, myoclonic seizures, optic atrophy, blindness, severe pyramidal signs 
and total loss of verbal communication around age 3-4. Spheroids are also observed in the 
terminal axons of grey matter and secondary dimetric demyelination of white matter. The 
diagnosis may be reached through the determination of oligosaccharides in urine and NAGA 
enzymatic activity assays in leucocytes or fibroblasts. (Khateeb et al., 2006) Many patients 
have been diagnosed with INAD in association with Schindler disease, showing that these 
conditions are not always established independently from each other. (Carpenter et al., 2012) 
MRI, EEG, enzymatic assays results and clinical features allow the differentiation of 
INAD from a few conditions that may be considered at the time of the diagnosis, such as 
metachromatic leukodystrophy, GM1 gangliosidosis, ceroid neuronal lipofuscinosis 
(infantile) and Leigh syndrome. (Gordon N et al., 2002 )  
Forty percent of INAD patients in a study by Morgan et al. presented high iron 
composition in the globus pallidus. According to this, we should consider INAD as a strong 
differential diagnosis, despite the inexistence of reports of PANK2 mutations in INAD 
patients. Moreover, we should highlight the aforementioned update of 44 PLA2G6 
independent mutations reported by Morgan et al.  
Currently, there is limited information regarding PLA2G6 mutations in Portugal. There 
seems to be a trend towards a specific PLA2G6 nonsense mutation. Also, it is possible to 
establish a diagnosis of INAD by prenatal diagnosis in mutation positive families. 
In 2008, a study from the University of Porto proposes a flowchart to assist on the 
establishment of INAD diagnosis, adapted to the portuguese reality. The study proposes an 
approach to all patients who present arrest or regression in psychomotor development 
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between age six months and three years, bilateral pyramidal tract signs, marked hypotonia and 
nystagmus. Hence, the patient only proceeds with genetic tests comprising PLA2G6 mutation 
detection, if EEG and/or brain MRI are found with typical INAD findings. If those show an 
atypical presentation, the physician should consider another diagnosis and repeat the EEG 3 
months later.  
If one moves forward onto genetic testing, one should consider that not identifying a 
causative mutation is not an exclusion for the diagnosis. Thus one may get a diagnosis 
confirmation of INAD when a PLA2G6 mutation is identified (redirecting the patient to 
genetic counseling) and still account a fair probability of INAD if mutation detection is 
negative. In order to ascertain this probability, we shall perform a skin biopsy, in which one 
should find the aforesaid findings. If the pathologist reports those as absent, one should, 
therefore, consider another diagnosis. On the other hand, upon diagnosis confirmation, more 
extensive molecular studies are required. (Carrilho et al., 2008) 
 
POPULATION AND METHODS 
 
We present a case series of 3 unrelated patients carrying the diagnosis of INAD. 
Detailed phenotypic characterization was performed, including family history, best-corrected 
visual acuity (BCVA), slit-lamp examination, fundus examination and fundus photography. 
Colour fundus photographies (35º) of both eyes (centered to the macula and to the 
optic nerve) were taken in order to document the features of these structures, with a Topcon 
TRC-50 IA Retinal Ophthalmic Camera. 
Genomic DNA was prepared from venous leukocytes and for genetic testing, coding 
exons and flanking intronic regions of the PLA2G6 gene was PCR-amplified, purified, and 
sequenced.  
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This study was approved by the local ethics committee and followed the tenets of the 
Declaration of Helsinki. Informed consent was obtained from the patient prior to collection of 
clinical data and genomic samples.  
 
RESULTS 
 
Clinical and molecular results are summarized in tables 1, 2 and 3. It is important to 
underscore that all patients present PLA2G6 nonsense mutations in either homozygosity or 
double heterozygosity. 
 
Table 1- Clinical Features 
 
Patient Sex 
and Birth  
date 
Family 
History 
Age at 
onset 
Initial 
symptoms 
First 
observation 
(age) 
Seizures (age) 
medication 
Ophthalmic 
Examination 
(age) 
Other 
Findings 
MBN 
Male 
15/03/2010 
N 15 M Loss of 
acquired skills 
(lost ability to 
walk) 
18 M 
Hypotonia, 
reflexes++, 
extensor 
plantar 
response 
Absent 37m 
Variable 
visual 
contact, 
esotropia, 
abolished 
pupilary 
reflexes, 
optic pallor 
Cerebellar 
atrophy 
AFLC 
Female 
13/12/2005 
N 30 M Loss of 
acquired skills 
(lost ability to 
walk with 
developmental 
regression) 
33 M 
 
Focal, 
generalized  
(7 years) 
 
Levetiracetam 
28m 
Normal 
visual 
contact, 
esotropia, 
limitation of 
abduction,  
temporal 
optic Pallor 
EMG: severe 
chronic motor 
neuronopathy. 
Muscle and 
nerve biopsy 
confirm 
diagnosis. 
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AJAS 
Female 
10/09/2005 
N 6 M Loss of 
acquired skills 
(lost ability to 
sit, with 
developmental 
regression) 
9 M 
Hypotonia, 
reflexes+, 
extensor 
plantar 
response 
Absent 28m 
Normal 
visual 
contact, 
esotropia, 
limitation of 
abduction,  
temporal 
optic pallor 
Muscle and 
nerve biopsy 
confirm 
diagnosis 
 
 
Table 2 – Ophthalmological follow-up 
 
Patient Sex and Birth  
date 
Family 
History 
Age 
at 
onset 
First 
observation 
(age) 
First Ophthalmic 
Examination (age) 
Final Ophthalmic observation 
(age) 
MBN 
Male 
15/03/2010 
N 15 M 18 M 
Hypotonia, 
reflexes++, 
extensor 
plantar 
response 
37 M 
Variable visual 
contact, ET, 
abolished 
pupillary reflexes, 
optic pallor 
48 M 
Poor visual contact (looks 
through) 
Abolished papillary reflexes. 
Variable ET. Optic atrophy 
with drop out NFL 
AFLC 
Female 
13/12/2005 
N 30 M 33 M 
 
28 M 
Normal visual 
contact, 
esotropia, 
limitation of 
abduction,  
temporal optic 
pallor 
8 Y 8 M 
Poor visual contact.  
Alternating esotropia. 
Limitation of vertical 
motility. Optic atrophy with 
considerable NFL drop-out 
AJAS 
Female 
10/09/2005 
N 6 M 9 M 
Hypotonia, 
reflexes+, 
extensor 
plantar 
response 
28 M 
Normal Visual 
Contact, 
ET, Limitation of 
Abduction,  
Temporal optic 
pallor 
6 Y.  
Age appropriate visual 
contact. Manifest latent 
nystagmus. Alternating 
esotropia. Temporal optic 
atrophy, worsening of NFL 
drop-out. 
 
Legend: Y: Years; M: months; ET: esotropia; NFL: nerve fiber layer 
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Table 3- Genetic Findings 
 
Patient Sex 
and Birth  
date 
Family History Gene PLA2G6 Polypeptide 
PLA2G6 
Mutation 
Type 
References 
MBN 
Male 
15/03/2010 
No 
consanguinity 
c.1442T>A 
c.2370T>G 
p.Leu481Gln 
p.Tyr790X 
Missense 
Nonsense 
Morgan et al 2006. Nat 
Genet.38(7): 752-4 
AFLC 
Female 
13/12/2005 
No 
consanguinity 
c.2370T>G 
Partial deletion 
involving 
exons 3 and 4 
p.Tyr790X 
p.251_G253del 
Nonsense 
Nonsense 
Morgan et al 2006. Nat 
Genet.38(7): 752-4 
AJAS 
Female 
10/09/2005 
Consanguinity
? 
c.2370T>G 
c.2370T>G 
p.Tyr790X 
p.Tyr790X 
Nonsense 
Nonsense 
Morgan et al 2006. Nat 
Genet.38(7): 752-4 
 
 
 
 
Figure 1: Left eye fundus image depicting optic disc pallor in the temporal 
half, vessels of normal caliber and normal retina. 
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DISCUSSION 
 
Carrilho et al reported a group of 10 caucasian portuguese patients (seven girls and 
three boys), all with very similar clinical features; ophthalmic findings also included those 
which we highlight: nystagmus, hypotonia, optic atrophy, and, less frequently (only 2), 
strabismus. All of them presented loss or arrest of acquired skills (to sit, to walk, to talk, 
depending on the age). (Carrilho et al., 2008) 
In our series, there is no history of pregnancy or perinatal complications. We report an 
early onset of the condition (from 6 to 30 months old). All patients presented with an evident 
development arrest/regression, reflected by loss of acquired skills according to the age (ability 
to sit/walk). This progressive motricity impairment remained, along with the appearance of 
other symptoms. The Porto’s series reveals similar age of onset (ranging from 6 to 18 months) 
with the same initial features of developmental arrest, and with 4 patients showing regression 
in acquired skills. 
In association with the developmental deficit, we highlight the presence of severe 
hypotonia in all patients. Visual behavior is usually maintained within normal limits during 
the initial phases of disease, however in our series one patient presented variable visual 
contact; this child also presented absence of pupillary reflexes, different from the clinical 
findings of the other two. There is no record of nystagmus in any of them, as well as any 
significant refractive error. Despite the absence of hyperopic refractive error,, all patients 
presented with esotropia. 
Summarizing the clinical presentation, we report some relevant and distinct features 
and ophthalmologic findings, such as the typical loss of acquired skills (stressing mainly 
motricity skills), progressive impairment of visual contact, presence of esotropia and absence 
of significant refractive error. 
CLINICAL AND MOLECULAR CHARACTERIZATION    
 OF INFANTILE NEUROAXONAL DYSTRHOPHY 
13 
 
 With regards to the fundus appearance, we observed a rapid progressive impairment of 
the optic pallor with a significant dropout of the nerve fibers layer, corresponding to the 
ganglion cells apoptosis. We were able to obtain autofluorescence imaging in one case (data 
not shown). No changes were observed in a normal autofluorescence pattern, which allows 
inferring that no significant disturbances are found in the external layers of the retina (retinal 
pigment epithelium and photoreceptors layers).  
 Hence, fundus findings in combination with knowledge of the physiopathology of 
generalized NBIAs, allows the suggestion that the rapidly progressive optic atrophy may be 
related to iron deposition in the ganglion cells. Such finding is also observed in other 
neurodegenerations secondary to cerebral iron accumulation, like PKAN, in which identical 
fundi are commonly observed.  
 Regarding the genetic findings, all patients present a common PLA2G6 mutations, 
reported by others (Carrilho et al, 2008; Morgan et al, 2006) which is also the most frequent 
mutation nonsense p2370>G  in the other Portuguese series (Carrilho et al, 2008) (there are 
4/10 patients with this mutation - 1 heterozygous and 3 homozygous). Curiously, the genetic 
change only truncates the C-terminal region of the protein, but apparently has significant 
function impact to the protein. This may be the result of abnormal folding of the protein 
which may compromise the appropriate position of the active motifs. The Y790X mutation 
may represent a hotspot and should be considered in the initial molecular diagnosis of every 
Portuguese INAD suspect. This mutation has been identified in cases of classic INAD and 
neurodegeneration with brain iron accumulation (Morgan et al, 2006). We should also 
underscore the fact that homozygous or double heterozygous missense mutations in the 
PLA2G6 gene have been associated with a  juvenile onset autosomal recessive Parkinson 
variant in chinese and japonese populations (Shi et al, 2012).. 
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 Unfortunately, one can only offer these patients supportive measures (physical and 
psychological support to relatives) in addition to medically controlling seizures, when they 
are present. Researches are trying to pursue a cure for this type of NBIA. Until now, no 
relevant findings were reported regarding INAD definitive treatment.  
 Concerning the resmainder of NBIAs, a recent study (Ge et al, 2011) presents some 
preliminary results with Deep Brain Stimulation of the subthalamic nuclei as a possible cure 
for some NBIA type 1 (PKAN- Hallervorden–Spatz syndrome). Although, this is a single 
case report, the authors refer this therapy with DBS of globus pallidus internus or thalamus as 
a method with partial improvement. Because improvement was seen, the authors assume an 
advantage sub-thalamic nuclei DBS over the traditionally intervened areas. (Ge et al., 2011) 
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